NCT03463551View on ClinicalTrials.gov

Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic

PHASE2UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2018

Primary Completion Date

September 30, 2019

Study Completion Date

March 31, 2020

Conditions
Acute Ischaemic Stroke
Interventions
DRUG

ABL-101

ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.

OTHER

0.9% NaCl

Placebo

Sponsors

Collaborators (1)

Aurum Biosciences Ltd
All Listed Sponsors
collaborator

University of Glasgow

OTHER

collaborator

Aurum Biosciences Ltd

UNKNOWN

lead

NHS Greater Glasgow and Clyde

OTHER

NCT03463551 - Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic | Biotech Hunter | Biotech Hunter